MAR 27, 2018 9:00 AM PDT

Proteomics profiling of post-translational modifications in early drug discovery

  • Group Leader, Proteomics Products and Services, Cell Signaling Technology
      Matt Stokes began his scientific career in 1994 as a high school student with an internship at New England BioLabs/Cell Signaling Technology where he worked through college. He received his B.A. in Biology from Colby College in Waterville, ME in 2000. He then pursued his interest in understanding the complexities of cellular signaling pathways at Harvard University in Cambridge, MA where he received his Ph.D. in Biochemistry in 2005. During this time, his work focused on elucidating mechanisms of the DNA damage response using Xenopus laevis egg extracts. Matt joined Cell Signaling Technology in 2005 as a scientist in the Cancer Discovery group, and moved to the Proteomics Group in 2009. Matt currently leads the Proteomics Products and Services Group, providing start-to-finish proteomics solutions for both academic and industry clients.
    • Senior Scientific Researcher, Microchemistry, Proteomics & Lipidomics (MPL), Genentech
        Lilian obtained her B.S. in Biochemistry and Molecular Biology from the University of California, Santa Cruz. Lilian joined Genentech in 2003 and currently serves as a Senior Scientific Researcher in the MPL group. During her time at Genentech, Lilian has made important contributions to large and small molecule drug development through her use of mass spectrometry proteomics.
      • Associate Director & Principal Scientist, Microchemistry, Proteomics & Lipidomics (MPL), Genentech
          Don obtained a B.S. in Biochemistry from University of Oklahoma and a Ph.D. in Pharmacology & Toxicology from the University of Arizona. His thesis work sparked a fascination with two topics that remain at the heart of his research - ubiquitin and mass spectrometry proteomics. He extended his work in these areas as a postdoctoral fellow at Harvard Medical School where he used mass spectrometry to characterize the composition of ubiquitin signals and their attachment to protein substrates. Since 2007, Don has been a member of the MPL (Microchemistry, Proteomics and Lipidomics) group at Genentech, currently serving as a Principal Scientist and Associate Director of Discovery Proteomics. His group focuses on implementing new technologies to explore cellular proteins and post-translational modifications. A key aim of the group is to understand how ubiquitin system functions in normal cell biology and human disease.


        DATE: March 27, 2018
        TIME: 09:00am PDT, 12:00pm EDT

        Advances in mass spectrometry instrumentation and sample handling methods have propelled proteomics and extended its utility for both basic biology and early drug development. Changes in protein abundance and post-translational modification state often reflect the activity of a novel therapeutic agent as well as the sensitivity/resistance of a biological system to treatment. For post-translational modifications, methods to enrich modified peptides from complex mixtures have played an important role. Chief among these is immunoaffinity enrichment, where antibodies directed against post-translational modifications (or remnants thereof) are used to capture analytes of interest for mass spectrometry analysis. To expand upon these methods, here we report on an automated PTMScan® immunoaffinity enrichment protocol, developed using the Phynexus MEA benchtop robot, for concurrent processing of up to twelve samples. System optimization has included interrogating the effects of peptide incubation, washing, and antibody-resin crosslinking on the sensitivity and specificity of this automated method. Using this technology in conjunction with Ubiquitin Remnant Motif (K-ε-GG), it is now possible to identify and quantify many >10,000 distinct ubiquitination events from cultured cells and tissue samples. This webinar will focus on the utility of the PTMScan method in early drug discovery and the future of automation in multiplexed analysis of cellular signaling.

        During this webinar, viewers will learn about:

        • How changes in post-translational modification can be used to assess activation states of novel therapeutic targets;
        • Benchtop robot automation of the PTMScan® immunoaffinity enrichment protocol, enabling concurrent processing of 12 samples;
        • Utility of the PTMScan® method for early drug discovery, and the future of automation in multiplexed analysis of cellular signaling.


        PTMScan® is a registered trademark of Cell Signaling Technology, Inc.




        Show Resources
        MAR 27, 2018 9:00 AM PDT

        Proteomics profiling of post-translational modifications in early drug discovery



        Cancer Research

        Molecular Biology

        Cell Biology


        Cell Culture




        Gene Expression

        Drug Discovery



        Cell Signaling / Transduction

        Cancer Therapeutics


        North America46%



        South America7%



        Registration Source

        Website Visitors55%

        Email Promotions21%

        Social Media Promotions11%

        WAVE Newsletter Promotion9%

        Website Banners2%

        Client/Sponsor Promotions1%

        Job Title


        Research Scientist15%



        Post Doc8%


        Facility/Department Manager6%

        Medical Doctor/Specialist5%

        Medical Laboratory Technician4%

        Lab Management3%

        Clinical Laboratory Scientist2%




        Academic Institution24%

        Research Institute13%

        Biotech Company10%



        Pharmaceutical Company4%

        Medical School4%

        Clinical Laboratory4%

        Medical Center3%

        Life Science Company2%

        Non-Profit Organization2%

        Industrial Company2%

        Contract Research Organization (Cro)1%

        Veterinary School1%


        Show Resources
        Show Resources
        • See more
        Connect with us